REJUVENATE BIO INC
Gene therapy platform for enhancing physical recovery, endurance, and cognitive performance in military operators
- Sector
- Biotech
- Headquarters
- San Diego, CA
- Latest Form D
- $19.5M, Jun 2026
- Total capital
- $50.2M
- Federal grants
- $9.9M
- 8 awards · 2017–2022
- Rank in peer group#54 of 514
- Private capital raised
- $34M
- 2 Form D · last Jun 2026
- 4 months since last filing
- Federal contracts
- $6.3M
- 3 awards · Defense
- Rank in Biotech#71 of 4373
- Granted patents
- 0
- 21 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$19.5M
- Federal grantDefense · Phase II · Improving Human Performance through Neuroenhancement (#2)$3M
- Federal contractDefense · SBIR Ph II Topic: Human Performance Optimization$2.1M
- Federal grantDefense · Phase II · Human Performance Enhancement$2.1M
- Private capital raisedForm D · SEC · 1st filing$14.6M
- Federal grantDefense · Phase II · Improving Human Performance through Neuroenhancement$1.4M
- Federal grantDefense · Phase II · Human Performance Optimization$1.4M
Show 6 earlier federal awards
- Federal contractDefense · STTR Ph II Topic&prototype Development - Human Performance Optimization$2.2M
- Federal grantDefense · Phase II · Enhanced Canine Performance, Protection and Survivability$1.4M
- Federal contractDefense · SBIR Ph II Topic&prototype Development Ussocom 17.2 Topic 0002$2M
- Federal grantDefense · Phase I · Improving Human Performance through Neuroenhancement$150K
- Federal grantDefense · Phase I · Human Performance Optimization$150K
- Federal grantDefense · Phase I · Enhanced Canine Performance, Protection and Survivability$100K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
41months
from REJUVENATE BIO INC’s first federal award to its first private round.
- First federal award · Nov 2017
- Defense · $100K
- First Form D · Apr 2021
- $14.6M · 1st Form D
- Awards before first raise
- 8 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#54 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Daniel OliverResearcherExecutive Officer, DirectorLinked by $3M in grants as PI
- Noah DavidsohnResearcherExecutive Officer, DirectorLinked by $6.9M in grants as PI
- David ZhuDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 21- PendingAptazyme-based Regulatable Gene Expression SystemsUSPTOApplication 19125842
- PendingGene Therapy Methods For Arrhythmogenic CardiomyopathyUSPTOApplication 19114132
- PendingFGF21 Gene Therapy And Methods ThereforUSPTOApplication 63761685
Show all 21 patent records
- Aptazyme-based Regulatable Gene Expression SystemsJun 18, 2026 · Application 19125842Pending
- Gene Therapy Methods For Arrhythmogenic CardiomyopathyApr 16, 2026 · Application 19114132Pending
- FGF21 Gene Therapy And Methods ThereforApplication 63761685Pending
- FGF21 Gene Therapy And Methods ThereforApplication 63647136Pending
- Bicistronic Gene Expression Systems And Methods Of UseApplication 63647134Pending
- Aptazyme-based Regulatable Gene Expression SystemsApplication PCTUS2023078621Pending
- Adeno-associated Virus CapsidsApplication PCTUS2023074729Pending
- Gene Therapy Methods For Treating Mitral Valve DiseaseApplication PCTUS2023074731Pending
- Gene Therapy Methods For Familial Partial LipodystrophyApplication PCTUS2023074732Pending
- Gene Therapy Methods For Arrhythmogenic CardiomyopathyApplication PCTUS2023074747Pending
- Gene Therapy Methods For Treating Mitral Valve DiseaseApplication 63503318Pending
- Aptazyme-based Regulatable Gene Expression SystemsApplication 63382165Pending
- Gene Therapy Methods For Treating Mitral Valve DiseaseApplication 63376472Pending
- Adeno-associated Virus CapsidsApplication 63376470Pending
- Gene Therapy Methods For Familial Partial LipodystrophyApplication 63376475Pending
- Gene Therapy Methods For Arrhythmogenic CardiomyopathyApplication 63376474Pending
- Gene Therapy Methods For Familial Partial LipodystrophyApplication 19114106Pending
- Gene Therapy Methods For Treating Mitral Valve DiseaseApplication 19114115Pending
- FGF21 Gene Therapy And Methods ThereforApplication PCTUS2025029353Pending
- Adeno-associated Virus CapsidsApplication 19114090Pending
- Bicistronic Gene Expression Systems And Methods Of UseApplication PCTUS2025029350Pending
Related companies, and why
- Applied Systems Engineering IncorporatedShares a founder: William Smith
- ATTOLLO ENGINEERING, LLCShares a founder: William Smith
- BHAWIN LLCShares a founder: William Smith
- BLACK CAPE, INC.Shares a founder: William Smith
- Inhibikase Therapeutics, Inc.Similar federal contract value in Biotech · $7.1M in contracts
- DYNAVAX TECHNOLOGIES CORPORATIONSimilar federal contract value in Biotech · $7.1M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .